Ad
related to: panitumumab- What is TUKYSA®?
Benefits of Treatment
How TUKYSA® Can Help
- Access To TUKYSA®
Find A Specialty Pharmacy
That Distributes TUKYSA®
- MOUNTAINEER Trial
Trial Design and Endpoints
TUKYSA® MOUNTAINEER Study
- Prescribing Information
Find Prescribing Information
And Other Resources For Physicians
- What is TUKYSA®?
Search results
Results From The WOW.Com Content Network
Panitumumab was approved by the European Medicines Agency (EMEA) in 2007, and by Health Canada in 2008, for "the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS". Panitumumab was the first monoclonal antibody to demonstrate the use of KRAS as a predictive biomarker.
[4] [5] The most common adverse reactions for sotorasib used in combination with panitumumab include rash, dry skin, diarrhea, stomatitis, fatigue, and musculoskeletal pain. [ 4 ] [ 9 ] Sotorasib is the first approved targeted therapy for people with tumors with any KRAS mutation, which accounts for approximately 25% of mutations in non-small ...
This monoclonal antibody –related article is a stub. You can help Wikipedia by expanding it.
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. [2]
Zalutumumab (proposed trade name HuMax-EGFR) is a fully human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFR). It is a product developed by Genmab in Utrecht, the Netherlands.
A phase 1 clinical trial in 2004 demonstrated the safety and tolerability of mapatumumab in cancer patients with advanced solid tumors or non-Hodgkin’s lymphoma, and supported further evaluation in phase 2 clinical trials, both as a single agent and in combination with chemotherapy. [4]
This monoclonal antibody –related article is a stub. You can help Wikipedia by expanding it.
Brigatinib is an inhibitor of ALK [3] and mutated EGFR. [5]ALK was first identified as a chromosomal rearrangement in anaplastic large cell lymphoma (ALCL). Genetic studies indicate that abnormal expression of ALK is a key driver of certain types of non-small cell lung cancer (NSCLC) and neuroblastomas, as well as ALCL.